Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19765483 | 1.00 | ATM (0.41) | ATMMAPTPOLBENPP2LMNA | |
| SCHEMBL25153145 | 1.00 | ATM (0.41) | ATMMAPTPOLBENPP2LMNA | |
| SCHEMBL16717657 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL16716952 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL16716948 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL23275047 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL19617642 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL16717660 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL20422022 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 | |
| SCHEMBL3645212 | 0.83 | MAPT (0.33) | ATMMAPTENPP2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, C5, TFPI | ATM 4421/4885MAPT 3066/4885POLB 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.